与myc结合亲和力高的已上市药物

MYC有所谓不可成药性，还没有专门的靶向药上市。

目前针对myc实际可行的治疗策略是根据患者除myc突变扩增外的其他突变，抑制其他靶点，如mtor、hsp90等，实现合成致死或蛋白降解。自救群里部分myc扩增的乳腺癌患者用了mtor抑制剂，确有疗效。
4 c; J% C4 m$ U  y- l0 d9 P
针对治疗myc还有一种办法是通过计算机虚拟筛选等办法，在已上市药物里找与myc结合亲和力高的药物。

; O7 W8 [) O, W- l+ X《In Silico, In Vitro, and In Vivo Investigations on Adapalene as Repurposed Third Generation Retinoid against Multiple Myeloma and Leukemia》这篇论文，通过Virtual Screening、Molecular Docking Analyses and Microscale Thermophoresis的办法，从FDA已经批准上市的1578种药物里，筛选出一些与MYC结合亲和力高的药物；其中一些药物与MYC的结合亲和力超过常用的c-MYC 抑制剂试剂 10058-F4 和 10074-G5(LBEs of −4.92 kcal/mol and −6.24 kcal/mol)。

下面是结合亲和力比较强的一些药物：
; I  Q/ I7 |% @. D

. B* x' _0 B0 _% w" Y2 u4 A% m
. K7 O+ {2 h; C- {; s4 }
其他一些研究的结论与这篇论文的结论是相印证的，试举几例如下：

( _9 y, L* n" ^* a( }
2 R  t* S- q! j  ?1、《Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors》

8 \0 j) f+ T& V1 }( X4 m6 o# c1 ]“MYC was identified as the most statistically repressed gene by DHE”
% e) s) ^: o% i; l% c
$ t+ I$ o: a4 d; R
" k3 W! R: Q4 P. H9 L, o
2、《Drug repurposing and prediction of multiple interaction types via graph embedding》
; T4 j. P0 I0 i- k5 Q
“Two FDA approved drugs, Dihydroergotamine (CHEMBL1732) and Indinavir Sulfate (CHEMBL1735), which are predicted by the DT2Vec+, might be able to target MYC and decrease its expression. ”


, S+ d9 ]1 s+ G; U) W
3、《Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells》

! H. _0 q6 |" T' k/ ~" ^! N“PNT induced apoptosis (increased sub G1 cells, and cleaved caspase3 and PARP), and suppressed protein expression of MCL1, cyclin D2 and c-myc, which were reversed by a proteasome inhibitor, MG132, suggesting enhanced proteasomal degradation by PNT. ”
. V) h3 \' @3 D
0 {6 O+ f3 `) Y+ e( \" m" R& P
; z' K# X& y# S( T1 s4、《 Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer》
; Q- a6 O4 x; V! L+ f
9 E; g& v+ f/ H1 ?. X# F Additionally, treatment with eribulin resulted in a decrease in c-myc expression and a trend
toward an increase in cdki p15。

% J- }3 Q& u4 _  w) x
5、《Atovaquone: an antiprotozoal drug suppresses primary and resistant breast tumor growth by inhibiting HER2/β-catenin signaling》

“We also observed a decrease in c-Myc expression in the tumors of atovaquone-treated mice”